molecules of the month


oral prodrug of serine _-lactamase inh.

in dev. for multidrug resistant bact. infection

from optimization of prior _-lactamase inh.

J. Med. Chem., Jul. 24, 2020

Entasis Therapeutics, Waltham, MA

Structure of orally available diazabicyclooctane inhibitor, ETX0282
1 min read

ETX0282 is an oral prodrug of a class A, C, and D serine β-lactamase inhibitor in clinical development for drug-resistant enterobacterial infections in combination with the beta-lactam drug cefpodoxime proxetil. Impressively ETX0282 had no observed adverse effect levels (NOAELs) of 500 mg/kg/day and 400 mg/kg/day in rat and dog, respectively, despite the reactive-looking nature of the strained bridged carbamate core and the monofluoroether. I was surprised by the chemical stability of the fluoroether moiety, which can be seen in the co-crystal structure.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: